Valuation dashboard for ImageneBio Inc (IMA) with P/E N/A, P/B 0.55, EV/EBITDA 0.72 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc.
Analysis Summary
ImageneBio Inc reported revenue of $800000 in the most recent fiscal year, growing at a 5-year CAGR of -38.6%.
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $4.93, IMA has negative trailing earnings (P/E not meaningful) and an ROE of -38.99%. Market capitalisation stands at $56M.
Balance sheet quality for IMA: current ratio of 12.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.55 |
| EV / EBITDA | 0.72 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IMA | ImageneBio Inc | $56M | 0.55 | -39.0% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $4.93 |
| Market Cap | $56M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -38.99% |
| Return on Invested Capital | -39.76% |
| Return on Assets | -34.52% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ARTV · CNTB · CNTX · IFRX · KLRS · MGX · OVID
Explore sector: Healthcare · Biotechnology
More sections of IMA: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks